Featuring perspectives from Prof Karim Fizazi and Dr Daniel George, moderated by Dr Elisabeth I Heath, including the following topics:

• Introduction (0:00)
• Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr George (3:25)
• Targeting AKT in Metastatic Prostate Cancer — Prof Fizazi (32:54)
• Tolerability and Other Practical Considerations with Capivasertib — Dr Heath (1:03:15)

CME information and select publications

Featuring perspectives from Ms Jamie Carroll, Prof Giuseppe Curigliano, Dr Marie E McDonnell and Dr Hope S Rugo, including the following topics:

• Introduction: Use of On-Body Glucose Monitoring Devices (0:00)
• Overview of Breast Cancer and Diabetes (9:39)
• PI3K/AKT/mTOR Pathway and Glucose Metabolism (19:28)
• Case Presentations — Part 1 (26:02)
• Current Data with Alpelisib, Capivasertib and Inavolisib (43:51)
• Prevention and Management of Hyperglycemia (1:02:17)
• Case Presentations — Part 2 (1:10:24)

CME information and select publications

Featuring patient case presentations by Dr Jacqueline T Brown and Dr Nazli Dizman, with commentary from Dr Matthew Milowsky, including the following topics:

• Case: A man in his mid 50s with metastatic recurrence of urothelial bladder cancer (UBC) after neoadjuvant cisplatin/gemcitabine receives first-line enfortumab vedotin (EV)/pembrolizumab (0:00)
• Case: A man in his early 50s with muscle-invasive bladder cancer (MIBC) receives adjuvant pembrolizumab, experiences disease progression and then receives EV monotherapy (12:33)
• Case: A man in his late 80s with recurrent metastatic UBC after pembrolizumab therapy for MIBC receives EV monotherapy at a reduced dose (24:07)

CME information and select publications